Integrated Biofluid Proteomics Identified Dynamic Functional Biomarkers of LRRK2-Linked Parkinson's Disease Progression
Xiao, C.; Shimizu, T.; huang, B.; Vu, D. T.; Itang, E.; Mann, M.; Karayel, O.; Yue, Z.
Show abstract
Leucine-rich repeat kinase 2 (LRRK2) variants are the most common cause of inherited Parkinsons disease (PD), and the hyperactivity of the LRRK2 variants represent a validated drug target for PD. The penetration of common LRRK2 variants is incomplete, underscoring the need for molecular biomarkers that predict disease onset and guide therapeutics development. Here, we analyzed large datasets of cerebrospinal fluid (CSF) and urinary proteomics from the Parkinsons Progression Markers Initiative (PPMI) and identified distinct lysosomal and immune protein signatures as potential biomarkers for LRRK2-linked PD (LRRK2 PD). Longitudinal analysis revealed that levels of specific lysosomal and immune proteins remained elevated in CSF during the prodromal phase but declined following clinical symptom onset. Furthermore, examination of multiple brain cell types from Lrrk2 mutant mice carrying disease variant (G2019S) showed heightened secretion of lysosomal proteins in microglia and astrocytes, but not neurons, supporting a glial origin and intrinsic LRRK2 mutant activity responsible for the elevated CSF lysosomal proteins. Furthermore, proteomics analysis of urine from humanized LRRK2G2019Stransgenic mice identified lysosome and glycosphingolipid protein signatures shared with human LRRK2 PD patients. Collectively, our integrated proteomics reveals dynamic changes of functional biofluid signatures for LRRK2 PD, which enables the determination of biomarkers for early disease onset. The humanized LRRK2G2019S mice provide a valuable platform for biomarker refinement and therapeutic development. One Sentence SummaryIntegrated human and mouse proteomic analyses identify dynamic lysosomal and immune biofluid signatures, possibly of glial origin, as functional biomarkers of LRRK2-linked Parkinsons disease progression, supported by a novel humanized LRRK2G2019S mouse model that recapitulates key urinary biomarker profiles.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Similar neuronal imprint and absence of cross-seeded partner fibrils in α-synuclein aggregates from MSA and Parkinson's disease brains 95%
- Neither alpha-synuclein-preformed fibrils derived from patients with GBA1 mutations nor the host murine genotype significantly influence seeding efficacy in the mouse olfactory bulb. 95%
- MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity 95%
Similar papers in this journal
- Multi-modal Proteomic Characterization of Lysosomal Function and Proteostasis in Progranulin-Deficient Neurons 96%
- Genome-wide dysregulation of histone acetylation in the Parkinsons disease brain 96%
- A Microglial Activity State Biomarker Panel Differentiates Ftd-Granulin And Ad From Control Cases 96%
Similar papers in this journal
- Modeling Alpha-Synuclein Pathology in a Human Brain-Chip to Assess Blood-Brain Barrier Disruption in Parkinson's Disease 96%
- Mitochondrial complex I deficiency stratifies idiopathic Parkinson's disease 95%
- Multi-Omic Analysis Reveals Lipid Dysregulation Associated with Mitochondrial Dysfunction in Parkinson's Disease Brain 95%
Similar papers in this journal
- Multifaceted proteome analysis at solubility, redox, and expression dimensions for target identification 94%
- Molecular determinants of protein pathogenicity at the single-aggregate level 92%
- RIG-I mediated neuron-specific IFN type 1 signaling in FUS-ALS induces neurodegeneration and offers new biomarker-driven individualized treatment options for (FUS-)ALS 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.